Literature DB >> 22495543

Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults.

John D Grabenstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22495543     DOI： 10.1093/cid/cis354

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  7 in total

1.  Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  Am J Prev Med       Date:  2020-01-28       Impact factor: 5.043

2.  Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  Vaccine       Date:  2019-03-04       Impact factor: 3.641

Review 3.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

4.  Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.

Authors:  Angela Domínguez; Jesús Castilla; Pere Godoy; Miguel Delgado-Rodríguez; Marc Saez; Núria Soldevila; Jenaro Astray; José María Mayoral; Vicente Martín; José María Quintana; Fernando González-Candelas; Juan Carlos Galán; Sonia Tamames; Ady Castro; Maretva Baricot; Olatz Garín; Tomas Pumarola
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

5.  The majority of adult pneumococcal invasive infections in Portugal are still potentially vaccine preventable in spite of significant declines of serotypes 1 and 5.

Authors:  Andreia N Horácio; Jorge Diamantino-Miranda; Sandra I Aguiar; Mário Ramirez; José Melo-Cristino
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

6.  Non-invasive pneumococcal pneumonia in Portugal--serotype distribution and antimicrobial resistance.

Authors:  Andreia N Horácio; Joana P Lopes; Mário Ramirez; José Melo-Cristino
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

7.  Pneumococcal serotype determines growth and capsule size in human cerebrospinal fluid.

Authors:  Annelies Müller; Anke Salmen; Suzanne Aebi; Linda de Gouveia; Anne von Gottberg; Lucy J Hathaway
Journal:  BMC Microbiol       Date:  2020-01-20       Impact factor: 3.605
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.